EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Oncogenic BRAF and KRAS Promote Global DNA Hypomethylation Through a Directed Pathway That Upregulates TET3

Ichiro Onoyama iD, W Rod Hardy, Shoichiro Takeishi, Lihua Julie Zhu, Yanglan Tan, Lloyd Hutchinson, Jianhong Ou, Leyuan Ma, Ching-Man Virbasius, Masafumi Yasunaga, Keiichi I Nakayama iD, Scott A Shaffer und 1 weitere

Cancer Science · 2026

DOI: 10.1111/cas.70434 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer Science, 2026. Verfasst von Ichiro Onoyama und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Molecular, Cell and Cancer Biology, University of Massachusetts Chan Medical School, Worcester, Massachusetts, USA. Hauptthemen laut MEDLINE: DNA Methylation, Proto-Oncogene Proteins B-raf, Dioxygenases, Proto-Oncogene Proteins p21(ras). Die Arbeit nennt 53 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NIGMS NIH HHS, Japan Society for the Promotion of Science, NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aberrant epigenetic modification is one of the characteristics of the cancer genome. DNA hypermethylation of cytosine‐phospho‐guanine (CpG) islands, a hallmark of cancer cells, is well‐studied and contributes to cancer development by silencing tumor suppressor genes. However, the mechanisms and biological significance of global DNA hypomethylation in cancer are still unclear. Here, using the v‐Raf murine sarcoma viral oncogene homolog B1 (BRAF) V600E knock‐in mouse models, we demonstrate that endogenous expression of oncogenic BRAFV600E in non‐transformed cells promotes global DNA hypomethylation by increasing the levels of ten‐eleven translocation 3 (TET3), which converts 5‐methylcytosine (5‐mC) into 5‐hydroxymethylcytosine (5‐hmC). Furthermore, TET3 is targeted for proteasomal degradation by F‐box and WD repeat domain containing 7 (FBXW7). BRAFV600E increases TET3 levels by inhibiting glycogen synthase kinase 3β (GSK3β), which phosphorylates TET3 and leads to its ubiquitination and proteasomal degradation. We further found elevated levels of TET3 and 5‐hmC in BRAFV600E‐induced mouse lung tumors and show that TET3 enhances the ability of BRAFV600E to induce the formation of lung tumors. Notably, endogenous expression of oncogenic Kirsten rat sarcoma virus (KRAS) G12D also promotes global DNA hypomethylation and induces lung tumors through a similar TET3‐mediated mechanism. Our findings elucidate one of the unknown mechanisms of global DNA hypomethylation promoted by oncogenic BRAF and KRAS and establish a role for TET3 to promote transformation in cooperation with BRAF and KRAS at an early stage of tumorigenesis.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

DNA MethylationProto-Oncogene Proteins B-rafDioxygenasesProto-Oncogene Proteins p21(ras)Proto-Oncogene ProteinsAnimalsMiceHumans5-MethylcytosineGene Expression Regulation, NeoplasticUp-RegulationGlycogen Synthase Kinase 3 betaLung NeoplasmsF-Box-WD Repeat-Containing Protein 7UbiquitinationEpigenesis, Genetic

Stichwörter der Autor:innen

BRAFDNA demethylationFBXW7KRAScarcinogenesisepigeneticsglobal DNA hypomethylation

Substanzen

Proto-Oncogene Proteins B-rafDioxygenasesProto-Oncogene Proteins p21(ras)Proto-Oncogene ProteinsTet3 protein, mouse5-MethylcytosineGlycogen Synthase Kinase 3 betaF-Box-WD Repeat-Containing Protein 75-hydroxymethylcytosineBraf protein, mouse

Autor:innen und Institutionen

  • Department of Molecular, Cell and Cancer Biology, University of Massachusetts Chan Medical School, Worcester, Massachusetts, USA.
  • Department of Gynecology and Obstetrics, Kyushu University Hospital, Fukuoka, Japan.
  • Anticancer Strategies Laboratory, TMDU Advanced Research Institute, Tokyo Medical and Dental University, Tokyo, Japan.
  • Program in Molecular Medicine and Department of Genomics and Computational Biology, University of Massachusetts Chan Medical School, Worcester, Massachusetts, USA.
  • Department of Biochemistry and Molecular Biotechnology, University of Massachusetts Chan Medical School, Worcester, Massachusetts, USA.
  • Department of Pathology, University of Massachusetts Chan Medical School, Worcester, Massachusetts, USA.

ORCID-Profile: Ichiro Onoyama, Keiichi I Nakayama

Förderung

  • NIGMS NIH HHS
  • Japan Society for the Promotion of Science
  • NIH HHS
  • National Institutes of Health

Zitieren

APA

Onoyama, I., Hardy, W. R., Takeishi, S., Zhu, L. J., Tan, Y., Hutchinson, L., Ou, J., Ma, L., Virbasius, C. M., Yasunaga, M., Nakayama, K. I., Shaffer, S. A., & Green, M. R. (2026). Oncogenic BRAF and KRAS Promote Global DNA Hypomethylation Through a Directed Pathway That Upregulates TET3. Cancer Science. https://doi.org/10.1111/cas.70434

Vancouver

Onoyama I, Hardy WR, Takeishi S, Zhu LJ, Tan Y, Hutchinson L, et al. Oncogenic BRAF and KRAS Promote Global DNA Hypomethylation Through a Directed Pathway That Upregulates TET3. Cancer Science. 2026. doi:10.1111/cas.70434

BibTeX
@article{Onoyama2026,
  author = {Onoyama, Ichiro and Hardy, W Rod and Takeishi, Shoichiro and Zhu, Lihua Julie and Tan, Yanglan and Hutchinson, Lloyd and Ou, Jianhong and Ma, Leyuan and Virbasius, Ching-Man and Yasunaga, Masafumi and Nakayama, Keiichi I and Shaffer, Scott A and Green, Michael R},
  title = {Oncogenic BRAF and KRAS Promote Global DNA Hypomethylation Through a Directed Pathway That Upregulates TET3},
  journal = {Cancer Science},
  year = {2026},
  doi = {10.1111/cas.70434}
}
Kostenlos starten →